How should a catheter-associated urinary tract infection be managed in a male patient currently receiving amoxicillin‑clavulanate?

Management of Catheter-Associated UTI in a Male Patient on Amoxicillin-Clavulanate

This patient requires immediate reassessment of antibiotic therapy with urine culture and susceptibility testing, as amoxicillin-clavulanate is not recommended as empirical therapy for catheter-associated UTI (CA-UTI) in males. 1

Immediate Actions Required

Obtain Urine Culture Before Changing Therapy

• Collect urine specimen for culture and susceptibility testing immediately before modifying antimicrobial therapy, as CA-UTI has a broader microbial spectrum with increased antimicrobial resistance compared to uncomplicated UTI 1
• If the catheter has been in place ≥2 weeks, replace it and obtain the culture specimen from the freshly placed catheter, as biofilm on old catheters may not accurately reflect bladder infection status 1

Replace the Catheter if Long-Term

• If the indwelling catheter has been in place ≥2 weeks and is still medically indicated, replace it before continuing antimicrobial therapy to hasten symptom resolution and reduce risk of subsequent bacteriuria and CA-UTI 1
• This intervention significantly decreases polymicrobial bacteriuria, shortens time to clinical improvement at 72 hours, and lowers CA-UTI recurrence rates within 28 days 1

Recommended Empirical Antibiotic Regimen

Switch to Guideline-Concordant Therapy

For CA-UTI with systemic symptoms in males, use combination therapy with:

• Amoxicillin plus an aminoglycoside, OR
• A second-generation cephalosporin plus an aminoglycoside, OR
• An intravenous third-generation cephalosporin 1

Why Amoxicillin-Clavulanate is Inadequate

• The 2024 European Association of Urology guidelines do not list amoxicillin-clavulanate as recommended empirical therapy for complicated UTI with systemic symptoms 1
• CA-UTI in males is classified as a complicated UTI with broader microbial spectrum including E. coli, Proteus spp., Klebsiella spp., Pseudomonas spp., Serratia spp., and Enterococcus spp., many with increased resistance 1
• While amoxicillin-clavulanate has FDA approval for complicated UTI 2, guideline recommendations prioritize more robust empirical coverage for CA-UTI specifically

Alternative Oral Option (If Appropriate)

• Ciprofloxacin may be used ONLY if: local resistance rates are <10%, the patient does not require hospitalization, treatment can be entirely oral, and the patient has not used fluoroquinolones in the last 6 months 1
• Do not use fluoroquinolones if the patient is from a urology department or has recent fluoroquinolone exposure 1

Treatment Duration

Standard Duration for Males

• Treat for 10-14 days in males with CA-UTI, as prostatitis cannot be excluded 1
• 7 days may be considered if the patient is hemodynamically stable, has been afebrile for ≥48 hours, and has prompt symptom resolution 1
• For patients with delayed clinical response, use the full 10-14 day course 1

Special Considerations

• A 5-day regimen of levofloxacin (750 mg daily) may be considered for patients with mild CA-UTI who are not severely ill, though data are insufficient for other fluoroquinolones 1
• Treatment duration applies regardless of whether the catheter remains in place or is removed 1

Tailoring Therapy Based on Culture Results

Adjust Antibiotics Once Susceptibilities Available

• Switch to targeted oral therapy based on culture and susceptibility results once the patient is clinically stable 1
• Narrow the spectrum to the most appropriate agent for the isolated uropathogen 1

Critical Pitfalls to Avoid

Do Not Treat Asymptomatic Bacteriuria

• If the patient has no symptoms (fever, rigors, altered mental status, flank pain, costovertebral angle tenderness, acute hematuria, pelvic discomfort, or suprapubic pain), do not treat with antimicrobials 1
• Treatment of asymptomatic catheter-associated bacteriuria does not prevent symptomatic episodes and promotes antimicrobial resistance 1, 3

Address Underlying Urological Abnormalities

• Management of urological abnormalities or complicating factors is mandatory for optimal CA-UTI treatment 1
• Remove the catheter as soon as medically appropriate, as catheterization duration is the most important risk factor for CA-UTI development 1, 3

Monitor for Urosepsis

• CA-UTI is the leading cause of secondary healthcare-associated bacteremia with approximately 10% mortality 1
• Approximately 20% of hospital-acquired bacteremias arise from the urinary tract 1